Melanoma Diagnostic Tests Market Research Report – Medical Devices Pipeline Assessment, 2017

“The Latest Research Report Melanoma Diagnostic Tests – Medical Devices Pipeline Assessment, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

About Melanoma Diagnostic Tests Market

GlobalData’s Medical Devices sector report, Melanoma Diagnostic Tests – Medical Devices Pipeline Assessment, 2017″ provides an overview of Melanoma Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Melanoma Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData’s team of industry experts.

Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1339341

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

– Extensive coverage of the Melanoma Diagnostic Tests under development

– The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

– The report reviews the major players involved in the development of Melanoma Diagnostic Tests and list all their pipeline projects

– The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage

– The report provides key clinical trial data of ongoing trials specific to pipeline products

– Recent developments in the segment / industry

Reasons to buy

The report enables you to –

– Formulate significant competitor information, analysis, and insights to improve R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of Melanoma Diagnostic Tests under development

– Develop market-entry and market expansion strategies

– Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline

– In-depth analysis of the products current stage of development, territory and estimated launch date

View Sample PDF @ https://www.marketresearchreports.biz/reports/1339341/melanoma-diagnostic-tests-medical-devices-pipeline-assessment-2017-market-research-reports.pdf

Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 8

2 Introduction 9

2.1 Melanoma Diagnostic Tests Overview 9

3 Products under Development 10

3.1 Melanoma Diagnostic Tests – Pipeline Products by Stage of Development 10

3.2 Melanoma Diagnostic Tests – Pipeline Products by Territory 11

3.3 Melanoma Diagnostic Tests – Pipeline Products by Regulatory Path 12

3.4 Melanoma Diagnostic Tests – Pipeline Products by Estimated Approval Date 13

3.5 Melanoma Diagnostic Tests – Ongoing Clinical Trials 14

4 Melanoma Diagnostic Tests – Pipeline Products under Development by Companies 15

4.1 Melanoma Diagnostic Tests Companies – Pipeline Products by Stage of Development 15

4.2 Melanoma Diagnostic Tests – Pipeline Products by Stage of Development 17

5 Melanoma Diagnostic Tests Companies and Product Overview 19

5.1 Abbott Diagnostics Company Overview 19

5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 19

5.2 Adaptive Biotechnologies Corp Company Overview 20

5.2.1 Adaptive Biotechnologies Corp Pipeline Products & Ongoing Clinical Trials Overview 20

5.3 Agilent Technologies Inc Company Overview 21

5.3.1 Agilent Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 21

5.4 BioMark Diagnostics Inc. Company Overview 22

5.4.1 BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview 22

5.5 BioMarker Strategies LLC Company Overview 23

5.5.1 BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 23

5.6 Biosceptre International Ltd Company Overview 25

5.6.1 Biosceptre International Ltd Pipeline Products & Ongoing Clinical Trials Overview 25

5.7 Ceres Nanosciences Inc Company Overview 26

5.7.1 Ceres Nanosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 26

5.8 Dana-Farber Cancer Institute Inc Company Overview 27

5.8.1 Dana-Farber Cancer Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 27

5.9 Digna Biotech SL Company Overview 28

5.9.1 Digna Biotech SL Pipeline Products & Ongoing Clinical Trials Overview 28

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/1339341

5.10 Exosomics Siena SpA Company Overview 29

5.10.1 Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview 29

5.11 Genomic Health Inc Company Overview 30

5.11.1 Genomic Health Inc Pipeline Products & Ongoing Clinical Trials Overview 30

5.12 Hospital Universitario Cruces Company Overview 31

5.12.1 Hospital Universitario Cruces Pipeline Products & Ongoing Clinical Trials Overview 31

5.13 Hummingbird Diagnostics GmbH Company Overview 32

5.13.1 Hummingbird Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 32

5.14 ImmunID SAS Company Overview 33

5.14.1 ImmunID SAS Pipeline Products & Ongoing Clinical Trials Overview 33

5.15 Institut Pasteur Company Overview 36

5.15.1 Institut Pasteur Pipeline Products & Ongoing Clinical Trials Overview 36

5.16 InterGenetics Inc Company Overview 37

5.16.1 InterGenetics Inc Pipeline Products & Ongoing Clinical Trials Overview 37

5.17 IV Diagnostics Inc Company Overview 38

5.17.1 IV Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 38

5.18 John Hopkins University Company Overview 39

5.18.1 John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 39

5.19 Louisville Bioscience, Inc. Company Overview 40

5.19.1 Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview 40

5.20 MDNA Life Sciences Inc Company Overview 41

5.20.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 41

5.21 Melanovus Oncology Inc Company Overview 42

5.21.1 Melanovus Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview 42

5.22 Memorial Sloan Kettering Cancer Center Company Overview 43

5.22.1 Memorial Sloan Kettering Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 43

5.23 MyCardio LLC Company Overview 44

5.23.1 MyCardio LLC Pipeline Products & Ongoing Clinical Trials Overview 44

5.24 Orion Genomics LLC Company Overview 45

5.24.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview 45

5.25 Oryzon Genomics SA Company Overview 46

5.25.1 Oryzon Genomics SA Pipeline Products & Ongoing Clinical Trials Overview 46

5.26 Pacific Edge Ltd Company Overview 48

5.26.1 Pacific Edge Ltd Pipeline Products & Ongoing Clinical Trials Overview 48

5.27 Protea Biosciences Group Inc Company Overview 49

5.27.1 Protea Biosciences Group Inc Pipeline Products & Ongoing Clinical Trials Overview 49

5.28 Qiagen NV Company Overview 52

5.28.1 Qiagen NV Pipeline Products & Ongoing Clinical Trials Overview 52

5.29 Roche Diagnostics International Ltd Company Overview 54

5.29.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 54

5.30 Rosetta Genomics Ltd Company Overview 58

5.30.1 Rosetta Genomics Ltd Pipeline Products & Ongoing Clinical Trials Overview 58

5.31 Sividon Diagnostics GmbH Company Overview 59

5.31.1 Sividon Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview 59

5.32 SomaLogic Inc Company Overview 60

5.32.1 SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 60

5.33 Treos Bio Inc Company Overview 61

5.33.1 Treos Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 61

5.34 University of California San Francisco Company Overview 62

5.34.1 University of California San Francisco Pipeline Products & Ongoing Clinical Trials Overview 62

5.35 University of Louisville Company Overview 63

5.35.1 University of Louisville Pipeline Products & Ongoing Clinical Trials Overview 63

5.36 University of Maryland Baltimore Company Overview 64

5.36.1 University of Maryland Baltimore Pipeline Products & Ongoing Clinical Trials Overview 64

5.37 Vanderbilt University Company Overview 65

5.37.1 Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview 65

5.38 Zymera, Inc Company Overview 66

5.38.1 Zymera, Inc Pipeline Products & Ongoing Clinical Trials Overview 66

6 Melanoma Diagnostic Tests – Recent Developments 67

6.1 Sep 05, 2017: Rosetta Genomics to Reduce Operating and Other Expenses 67

6.2 Aug 31, 2017: BioMarker Strategies Announces Two New Patents Granted in Japan, For the Companys Core Diagnostics Technology PathMAP 67

6.3 Aug 30, 2017: bioMerieux – First-Half 2017 Results 68

6.4 Aug 30, 2017: GSK responds to UK Life Sciences Industrial Strategy 71

6.5 Aug 22, 2017: Protea Expands Clinical Study for New Melanoma Test 71

6.6 Aug 15, 2017: Agilent Technologies Reports Third-Quarter Fiscal Year 2017 Financial Results 72

6.7 Aug 08, 2017: HTG Molecular Diagnostics Reports Second Quarter 2017 Results 73

6.8 Aug 01, 2017: Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress 73

6.9 Jul 31, 2017: AtCor Signs New Agreement Major entry point into New York health systems market 75

6.10 Jul 28, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2017 75

6.11 Jul 27, 2017: Adaptive Biotechnologies Expands Leadership to Bolster Integration of Immune Profiling into Clinical Care Setting 77

6.12 Jul 27, 2017: QIAGEN Reports Results for Second Quarter and First Half of 2017 77

6.13 Jul 26, 2017: GSK delivers further progress in Q2 and sets out new priorities for the Group 81

6.14 Jul 25, 2017: Karenann Terrell appointed Chief Digital & Technology Officer, GSK 87

6.15 Jul 25, 2017: Quest Diagnostics Reports Second Quarter 2017 Financial Results, Raises 2017 Financial Outlook 87

6.16 Jul 21, 2017: GSK announces Board and Committee changes 87

6.17 Jul 20, 2017: bioMerieux – Second-Quarter 2017 Business Review 88

6.18 Jul 20, 2017: Professor John Spencers Lab to Carry Out Vital Skin Cancer Research Thanks to New Grant 90

6.19 Jul 18, 2017: Hans E. Bishop to Join Agilent’s Board of Directors 91

6.20 Jul 06, 2017: Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China 92

6.21 Jun 19, 2017: GSK confirms start date for Luke Miels 92

6.22 Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation 92

6.23 Jun 01, 2017: MolecularMD achieves status as an ArcherDX Certified Service Provider and expands offering of novel NGS chemistries 92

6.24 May 22, 2017: Agilent Technologies Reports Second-Quarter Fiscal Year 2017 Financial Results 93

6.25 May 16, 2017: Oryzon announces appointment of new Chief Medical Officer and expansion of its Medical Department 94

6.26 May 15, 2017: HTG Molecular Diagnostics Reports First Quarter 2017 Results 94

6.27 May 09, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2017 95

6.28 May 09, 2017: Genomic Health Announces First Quarter 2017 Financial Results and Reports Recent Business Progress 97

6.29 May 04, 2017: Agilent Technologies Receives Multiple Awards at Scientific Conference in China 98

6.30 May 02, 2017: QIAGEN reports results for first quarter 2017 99

6.31 May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results 101

6.32 May 01, 2017: Rosetta Genomics Expands Patent Portfolio in Europe and Japan 103

6.33 Apr 26, 2017: GSK delivers another quarter of continued progress 103

6.34 Apr 20, 2017: Quest Diagnostics Reports First Quarter 2017 Financial Results, Raises 2017 Financial Outlook 107

6.35 Apr 20, 2017: bioMerieux – First-Quarter 2017 Business Review 107

6.36 Apr 18, 2017: Protea Announces 2016 Year End Results 109

6.37 Apr 05, 2017: SomaLogic announces the appointment of long-time Board member as Chief Executive Officer 110

6.38 Apr 04, 2017: GSK responds to Cyclone Debbie 111

6.39 Mar 30, 2017: Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results 111

6.40 Mar 23, 2017: HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2016 Results 114

6.41 Mar 20, 2017: Agilent Technologies Hires Samraat “Sam” Raha to Head Strategy and Corporate Development 115

6.42 Mar 15, 2017: Agilent Technologies Board of Directors Elects Koh Boon Hwee as New Chairman 115

6.43 Mar 14, 2017: Agilent Technologies Receives 2017 Scientists Choice Award for Best Webinar Series 116

6.44 Mar 07, 2017: HTG Molecular Diagnostics Appoints New Chair of the Board of Directors 117

6.45 Mar 01, 2017: bioMerieux – 2016 Financial Results 117

6.46 Feb 24, 2017: ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016 121

6.47 Feb 21, 2017: Agilent Technologies Receives Dow’s Western Canada Science and Technical Excellence Conference Awards (WesTEC) for Technical Excellence and Innovation 122

6.48 Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms 122

6.49 Feb 14, 2017: Agilent Technologies Reports First-Quarter 2017 Results 123

6.50 Feb 14, 2017: Genomic Health Announces 2016 Fourth Quarter and Year-End Financial Results, Provides 2017 Financial Outlook 124

6.51 Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016 126

6.52 Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results 145

6.53 Feb 01, 2017: QIAGEN Reports Results for Fourth Quarter and Full-year 2016 146

6.54 Jan 26, 2017: Quest Diagnostics Reports Fourth Quarter And Full Year 2016 Financial Results; Provides Guidance For Full Year 2017 150

6.55 Jan 26, 2017: Quest Diagnostics Partners With Montefiore Health System to Deliver High-Value, Innovative Laboratory Services 151

6.56 Jan 19, 2017: bioMerieux – Fourth-Quarter 2016 Business Review 151

6.57 Jan 19, 2017: Abbas Hussain to leave GSK 153

6.58 Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK 154

6.59 Dec 21, 2016: Agilent Technologies Receives Top Innovation Award from The Analytical Scientist 155

6.60 Dec 19, 2016: GSK announces Board changes 155

6.61 Dec 15, 2016: Quest Diagnostics Board of Directors Elects Stephen H. Rusckowski Chairman of the Board 156

6.62 Nov 24, 2016: Pacific Edge Interim Results to 30 September 2016 156

6.63 Nov 22, 2016: Protea Announces Third Quarter 2016 Results 158

6.64 Nov 15, 2016: Agilent Technologies Reports Fourth-Quarter 2016 Results 158

6.65 Nov 14, 2016: HTG Molecular Diagnostics Reports Third Quarter 2016 Results 159

6.66 Nov 11, 2016: Quest Diagnostics Raises Revenue Growth Outlook, Increases Dividend at 2016 Investor Day 160

6.67 Nov 10, 2016: Protea Appoints David Halverson As President 161

6.68 Nov 07, 2016: Pierre Boulud appointed Corporate Vice Presidentof the Asia Pacific region at bioMerieux 162

6.69 Nov 02, 2016: QIAGEN Reports Results for Third Quarter and First Nine Months of 2016 162

6.70 Nov 02, 2016: QIAGEN launches restructuring initiatives, revises outlook for 2016 earnings and provides initial net sales and adjusted earnings guidance for 2017 165

6.71 Nov 01, 2016: Genomic Health Reports Third Consecutive Quarter of Double-Digit Revenue Growth in Announcement of Third Quarter 2016 Financial Results 166

6.72 Nov 01, 2016: Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results 167

6.73 Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016 168

6.74 Oct 24, 2016: ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2016 175

6.75 Oct 20, 2016: bioMerieux-Business Review for the nine months ended September 30, 2016 176

6.76 Oct 20, 2016: Quest Diagnostics Reports Third Quarter 2016 Financial Results 179

6.77 Oct 20, 2016: Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer 180

6.78 Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare 181

6.79 Sep 29, 2016: Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy 182

6.80 Sep 26, 2016: Rosetta Genomics Reports 2016 Second Quarter Financial Results 182

7 Appendix 185

7.1 Methodology 185

7.2 About GlobalData 188

7.3 Contact Us 188

7.4 Disclaimer 188

Buy Now This Report From Here @ https://www.researchmoz.com/checkout?rep_id=1339341&licType=S

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Leave a Reply

Designed by CyFocus.com
Powered by CyFocus.net